| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
9V
2 T Cells In Vitro and in SCID Mice In Vivo1
* Institute of Immunology, Universitätsklinikum Schleswig-Holstein Campus Kiel, Germany; and
German Cancer Research Center, Heidelberg, Germany
Human V
9V
2 T cells are selectively activated by bacterial phosphoantigens and aminobisphosphonates and exert potent cytotoxicity toward various tumor cells. In this study we have characterized the cytotoxic reactivity of T cell lines established from healthy donors by stimulation with aminobisphosphonate alendronate toward melanoma MeWo and pancreatic adenocarcinomas Colo357 and PancTu1 lines in vitro and in vivo upon adoptive transfer into SCID mice. Lysis of all tumor cells was enhanced when effector cells were preactivated with phosphoantigens. Recognition of MeWo was TCR dependent, as shown by anti-TCR Ab blockade, whereas only the phosphoantigen-mediated increased, but not the basal, lysis of Colo357 and PancTu1 was inhibited by anti-TCR Ab. Furthermore, lysis of Colo357, but not that of MeWo or PancTu1, was completely inhibited by the pan-caspase inhibitor zVAD, indicating different recognition and effector mechanisms involved in the T cell/tumor cell interactions. Upon transfer into SCID mice, alendronate-activated T cells given together with IL-2 and alendronate significantly prolonged the survival of SCID mice inoculated with human tumor cells. The best results were thus obtained when T cells were repetitively given five times over a period of 30 days. With this protocol, human T cells prolonged the mean survival of mice inoculated with MeWo melanoma from 28.5 to 87.3 days (p < 0.0001) and in the case of PancTu1 adenocarcinoma from 23.0 to 48.4 days (p < 0.0001). We conclude that an effective T cell-based immunotherapy might require activation of endogenous T cells with aminobisphosphonate (or phosphoantigen) and IL-2, followed by adoptive transfer of in vitro expanded T cells.
This article has been cited by other articles:
|
|
 |
|
  A. A.Z. Alexander, A. Maniar, J.-S. Cummings, A. M. Hebbeler, D. H. Schulze, B. R. Gastman, C. D. Pauza, S. E. Strome, and A. I. Chapoval Isopentenyl Pyrophosphate-Activated CD56+ {gamma}{delta} T Lymphocytes Display Potent Antitumor Activity toward Human Squamous Cell Carcinoma Clin. Cancer Res., July 1, 2008; 14(13): 4232 - 4240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Holderness, L. Jackiw, E. Kimmel, H. Kerns, M. Radke, J. F. Hedges, C. Petrie, P. McCurley, P. M. Glee, A. Palecanda, et al. Select Plant Tannins Induce IL-2R{alpha} Up-Regulation and Augment Cell Division in {gamma}{delta} T Cells J. Immunol., November 15, 2007; 179(10): 6468 - 6478. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Dieli, D. Vermijlen, F. Fulfaro, N. Caccamo, S. Meraviglia, G. Cicero, A. Roberts, S. Buccheri, M. D'Asaro, N. Gebbia, et al. Targeting Human {gamma}{delta} T Cells with Zoledronate and Interleukin-2 for Immunotherapy of Hormone-Refractory Prostate Cancer Cancer Res., August 1, 2007; 67(15): 7450 - 7457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Kabelitz, D. Wesch, and W. He Perspectives of {gamma}{delta} T Cells in Tumor Immunology Cancer Res., January 1, 2007; 67(1): 5 - 8. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Wesch, S. Beetz, H.-H. Oberg, M. Marget, K. Krengel, and D. Kabelitz Direct Costimulatory Effect of TLR3 Ligand Poly(I:C) on Human {gamma}{delta} T Lymphocytes J. Immunol., February 1, 2006; 176(3): 1348 - 1354. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. L. Havran The Biology of {gamma}{delta} T Cells: What Is the Relationship between {gamma}{delta} T Cells and Cancer? Will an Increased Number and/or Function of {gamma}{delta} T Cells Result in Lower Cancer Incidence? J. Nutr., December 1, 2005; 135(12): 2909S - 2909S. [Full Text] [PDF]
|
|
|
|
|
|
B. Rincon-Orozco, V. Kunzmann, P. Wrobel, D. Kabelitz, A. Steinle, and T. Herrmann Activation of V{gamma}9V{delta}2 T Cells by NKG2D J. Immunol., August 15, 2005; 175(4): 2144 - 2151. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
